About: http://data.cimple.eu/news-article/7f05a372c0a565e33f4a05356c72308ec1eeb0b63c2f79880aab8bb1     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • German pharmaceutical giant Merck and a US partner reported promising results Saturday in trials of a drug administered orally to fight Covid-19, saying it helps reduce patients' viral load. "At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data," said Wendy Painter, chief medical officer of the US firm, Ridgeback Biotherapeutics. In January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, including a pill-based one called molnupiravir, which it has developed with Ridgeback Biotherapeutics. This drug caused a significant drop in patients' viral load after five days of treatment with it, Merck said at a meeting with infectious disease experts. This Phase 2a test -- drug trials have three stages before a product can be approved -- was carried out among 202 non-hospitalized people with symptoms of Covid-19. There was no alert in terms of safety, and of four serious adverse events that were reported, none were considered to be related to taking this drug, Ridgeback said. Anti-viral oral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza) are sometimes prescribed for seasonal flu but researchers have yet to come up with something similar to fight the coronavirus. The findings of this study -- a quicker decrease in viral load among individuals with early-stage Covid-19 who are treated with molnupiravir -- are promising, said William Fischer, lead investigator of the study and a professor of medicine at the University of North Carolina. "If supported by additional studies, (they) could have important public health implications, particularly as the SARS-CoV-2 virus continues to spread and evolve globally," Fischer added. Merck is also working on another oral Covid treatment called MK-711. Preliminary results from clinical trials with it show a more than 50 percent reduction in risk of death or respiratory trouble in patients hospitalized with moderate to severe Covid-19, the company said in January. juj/tu/dw/mdl
schema:headline
  • Oral Covid treatment yields promising trial data: drugmakers
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software